Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter Formigenes
NCT ID: NCT01300039
Last Updated: 2011-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2003-01-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Cathepsin X in Infection With the Helicobacter Pylori
NCT01137942
Pathogen-microbiome Interaction During Helicobacter Pylori Infection
NCT05121025
Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli
NCT01820793
Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis
NCT03179384
Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments
NCT01703299
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Design, setting, participants, \& measurements: The effect of antibiotics on OF colonization was compared in 2 groups: a group receiving antibiotics for gastric infection with Helicobacter pylori (HP) and a group without HP that not receiving antibiotics. OF colonization in stool was detected by oxalate degradation at baseline and after 1 and 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antibiotics for H. pylori
Patients who underwent upper endoscopy and were found to have H. pylori, and were then to be treated with antibiotics for eradication of H. pylori
No interventions assigned to this group
Control group, no H. pylori
Patients who underwent upper endoscopy and found to not have H. pylori, and then would not receive antibiotics
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* undergoing upper endoscopy
* H. pylori present or absent on gastric histology
* stool positive for Oxalobacter formigenes
Exclusion Criteria
* stool negative for Oxalobacter formigenes
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA New York Harbor Healthcare System
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
New York Harbor VA Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David S Goldfarb, MD
Role: PRINCIPAL_INVESTIGATOR
New York Harbor VA Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
573
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.